Search

Your search keyword '"Takei, Makoto"' showing total 14 results
Start Over Author "Takei, Makoto" Publisher wiley
14 results on '"Takei, Makoto"'

1. Cardiovascular vs. non‐cardiovascular deaths after heart failure hospitalization in young, older, and very old patients

Author

Nakamaru, Ryo, primary, Shiraishi, Yasuyuki, additional, Sandhu, Alexander T., additional, Heidenreich, Paul A., additional, Shoji, Satoshi, additional, Kohno, Takashi, additional, Takei, Makoto, additional, Nagatomo, Yuji, additional, Nakano, Shintaro, additional, Kohsaka, Shun, additional, and Yoshikawa, Tsutomu, additional

Published
2022
Full Text
View/download PDF

3. Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [18F]PM‐PBB3 for clinical applications

Author

Kawamura, Kazunori, Hashimoto, Hiroki, Furutsuka, Kenji, Ohkubo, Takayuki, Fujishiro, Tomoya, Togashi, Takahiro, Arashi, Daisuke, Sakai, Toshiyuki, Muto, Masatoshi, Ogawa, Masanao, Kurihara, Yusuke, Nengaki, Nobuki, Takei, Makoto, Nemoto, Kazuyoshi, Higuchi, Makoto, Ming-Rong, Zhang, Kazunori, Kawamura, Hiroki, Hashimoto, Kenji, Furutsuka, Daisuke, Arashi, Masatoshi, Muto, Masanao, Ogawa, Nobuki, Nengaki, Makoto, Takei, Kazuyoshi, Nemoto, Makoto, Higuchi, and Zhang, Ming-Rong

Abstract

Recently, we produced 11C‐labeled 2‐((1E,3E)‐4‐(6‐(methylamino)pyridin‐3‐yl)buta‐1,3‐dienyl)benzo[d]thiazol‐6‐ol ([11C]PBB3) as a clinically useful positron emission tomography (PET) tracer for in vivo imaging of tau pathologies in the human brain. To overcome the limitations (i.e., rapid in vivo metabolism and short half‐life) of [11C]PBB3, we further synthesized 18F‐labeled 1‐fluoro‐3‐((2‐((1E,3E)‐4‐(6‐(methylamino)pyridine‐3‐yl)buta‐1,3‐dien‐1‐yl)benzo[d]thiazol‐6‐yl)oxy)propan‐2‐ol ([18F]PM‐PBB3). [18F]PM‐PBB3 is also a useful tau PET tracer for imaging tau pathologies. In this study, we developed a routine radiosynthesis and quality control testing of [18F]PM‐PBB3 for clinical applications. [18F]PM‐PBB3 was synthesized by direct 18F‐fluorination of the tosylated derivative, followed by removal of the protecting group. [18F]PM‐PBB3 was obtained with sufficient radioactivity (25 ± 6.0% of the nondecay‐corrected radiochemical yield at the end of synthesis, EOS), radiochemical purity (98 ± 0.6%), and molar activity (350 ± 94 GBq/μmol at EOS; n = 53). Moreover, [18F]PM‐PBB3 consistently retained >95% of radiochemical purity for 60 min without undergoing photoisomerization using a new UV‐cutoff light (yellow light) fixed in the hot cell to monitor the synthesis. All the results of the quality control testing for the [18F]PM‐PBB3 injection complied with our in‐house quality control and quality assurance specifications. We have accomplished >200 production runs of [18F]PM‐PBB3 in our facility for various research purposes.

Published
2020

4. Automated radiosynthesis of [ 11 C]MTP38—a phosphodiesterase 7 imaging tracer—using [ 11 C]hydrogen cyanide for clinical applications

Author

Kawamura, Kazunori, primary, Hashimoto, Hiroki, additional, Ohkubo, Takayuki, additional, Hanyu, Masayuki, additional, Ogawa, Masanao, additional, Nengaki, Nobuki, additional, Arashi, Daisuke, additional, Kurihara, Yusuke, additional, Fujishiro, Tomoya, additional, Togashi, Takahiro, additional, Sakai, Toshiyuki, additional, Muto, Masatoshi, additional, Takei, Makoto, additional, Ishii, Hideki, additional, Saijo, Takeaki, additional, Matsumura, Takehiko, additional, Obokata, Naoyuki, additional, and Zhang, Ming‐Rong, additional

Published
2022
Full Text
View/download PDF

5. Phenomapping in patients experiencing worsening renal function during hospitalization for acute heart failure

Author

Yagi, Ryuichiro, primary, Takei, Makoto, additional, Kohsaka, Shun, additional, Shiraishi, Yasuyuki, additional, Ikemura, Nobuhiro, additional, Shoji, Satoshi, additional, Niimi, Nozomi, additional, Higuchi, Satoshi, additional, Goda, Ayumi, additional, Kohno, Takashi, additional, Nagatomo, Yuji, additional, Nishihata, Yosuke, additional, Sujino, Yasumori, additional, Saji, Mike, additional, Ikegami, Yukinori, additional, Nakano, Shintaro, additional, Takahashi, Toshiyuki, additional, Fukuda, Keiichi, additional, and Yoshikawa, Tsutomu, additional

Published
2021
Full Text
View/download PDF

6. Epigenetic barrier against the propagation of fluctuating gene expression in embryonic stem cells

Author

Saito, Yuki, primary, Kunitomi, Akira, additional, Seki, Tomohisa, additional, Tohyama, Shugo, additional, Kusumoto, Dai, additional, Takei, Makoto, additional, Kashimura, Shin, additional, Hashimoto, Hisayuki, additional, Yozu, Gakuto, additional, Motoda, Chikaaki, additional, Shimojima, Masaya, additional, Egashira, Toru, additional, Oda, Mayumi, additional, Fukuda, Keiichi, additional, and Yuasa, Shinsuke, additional

Published
2017
Full Text
View/download PDF

7. Impaired respiratory function in MELAS‐induced pluripotent stem cells with high heteroplasmy levels

Author

Kodaira, Masaki, primary, Hatakeyama, Hideyuki, additional, Yuasa, Shinsuke, additional, Seki, Tomohisa, additional, Egashira, Toru, additional, Tohyama, Shugo, additional, Kuroda, Yusuke, additional, Tanaka, Atsushi, additional, Okata, Shinichiro, additional, Hashimoto, Hisayuki, additional, Kusumoto, Dai, additional, Kunitomi, Akira, additional, Takei, Makoto, additional, Kashimura, Shin, additional, Suzuki, Tomoyuki, additional, Yozu, Gakuto, additional, Shimojima, Masaya, additional, Motoda, Chikaaki, additional, Hayashiji, Nozomi, additional, Saito, Yuki, additional, Goto, Yu-ichi, additional, and Fukuda, Keiichi, additional

Published
2015
Full Text
View/download PDF

8. Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe18F-FITM

Author

Xie, Lin, primary, Yui, Joji, additional, Fujinaga, Masayuki, additional, Hatori, Akiko, additional, Yamasaki, Tomoteru, additional, Kumata, Katsushi, additional, Wakizaka, Hidekatsu, additional, Furutsuka, Kenji, additional, Takei, Makoto, additional, Jin, Zhao-Hui, additional, Furukawa, Takako, additional, Kawamura, Kazunori, additional, and Zhang, Ming-Rong, additional

Published
2014
Full Text
View/download PDF

13. Role of stiff atrium in elucidating diastolic dysfunction in Fontan circulation. Letter regarding the article 'Exercise catheterization in adults post-Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology'.

Author

Takei M

Subjects
Humans, Cardiac Catheterization methods, Adult, Diastole, Hemodynamics physiology, Heart Defects, Congenital physiopathology, Heart Defects, Congenital surgery, Exercise Test methods, Fontan Procedure, Heart Atria physiopathology
Published
2024
Full Text
View/download PDF

14. Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [ 18 F]PM-PBB3 for clinical applications.

Author

Kawamura K, Hashimoto H, Furutsuka K, Ohkubo T, Fujishiro T, Togashi T, Arashi D, Sakai T, Muto M, Ogawa M, Kurihara Y, Nengaki N, Takei M, Nemoto K, Higuchi M, and Zhang MR

Abstract

Recently, we produced 11 C-labeled 2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([ 11 C]PBB3) as a clinically useful positron emission tomography (PET) tracer for in vivo imaging of tau pathologies in the human brain. To overcome the limitations (i.e., rapid in vivo metabolism and short half-life) of [ 11 C]PBB3, we further synthesized 18 F-labeled 1-fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridine-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol ([ 18 F]PM-PBB3). [ 18 F]PM-PBB3 is also a useful tau PET tracer for imaging tau pathologies. In this study, we developed a routine radiosynthesis and quality control testing of [ 18 F]PM-PBB3 for clinical applications. [ 18 F]PM-PBB3 was synthesized by direct 18 F-fluorination of the tosylated derivative, followed by removal of the protecting group. [ 18 F]PM-PBB3 was obtained with sufficient radioactivity (25 ± 6.0% of the nondecay-corrected radiochemical yield at the end of synthesis, EOS), radiochemical purity (98 ± 0.6%), and molar activity (350 ± 94 GBq/μmol at EOS; n = 53). Moreover, [ 18 F]PM-PBB3 consistently retained >95% of radiochemical purity for 60 min without undergoing photoisomerization using a new UV-cutoff light (yellow light) fixed in the hot cell to monitor the synthesis. All the results of the quality control testing for the [ 18 F]PM-PBB3 injection complied with our in-house quality control and quality assurance specifications. We have accomplished >200 production runs of [ 18 F]PM-PBB3 in our facility for various research purposes., (© 2020 John Wiley & Sons, Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results